News
The U.S. Food and Drug Administration has approved Bravecto Quantum, a new shot that protects dogs six months or older ...
The Food and Drug Administration (FDA) can maintain its high bar for safety and efficacy, and also cut the waste and ...
A long-acting flea and tick treatment from Merck Animal Health has earned approval for dogs at least six months old from the ...
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
When the FDA unexpectedly uploaded around 200 drug rejection letters this week, the regulator provided a rare glimpse in | ...
Happy Friday. Today, we talk about the stem cell fire sale at CIRM, and about the FDA’s move to release a limited batch of ...
FDA Commissioner Marty Makary suggests his agency may expedite drug reviews for manufacturers reducing U.S. prices to global ...
The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...
The letters, many of which were already available online, detail why the regulators initially declined to approve some drugs.
Fluralaner for extended-release injectable suspension (Bravecto Quantum) is also indicated for treatment of lone star tick in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results